Quarry LP’s Nurix Therapeutics NRIX Stock Holding History

Quarry LP’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,500	Closed	-$56.2K	–	1894
2024 Q3	$56.2K	Buy	2,500 +2,435	+3,746%	+$55.2K	0.01%	672
2024 Q2	$1.36K	Buy	+65	New	+$1.01K	﹤0.01%	1670

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quarry LP's NRIX Position: Q4 2024 in Review

Quarry LP sold out of Nurix Therapeutics (NRIX) in Q4 2024, closing a stake of 2,500 shares — an estimated $56.2K sold.

Quarry LP first reported a position in NRIX in Q2 2024 and held it in 2 quarters. The position peaked at $56.2K in Q3 2024. 175 funds tracked by Wall St. Rank hold NRIX as of Q4 2024.

Quarry LP reported no remaining Nurix Therapeutics position as of Q4 2024 after selling out during the quarter.
Quarry LP sold 2,500 Nurix Therapeutics shares in Q4 2024, an estimated $56.2K.
Quarry LP first reported a position in Nurix Therapeutics in Q2 2024 and held it in 2 quarters.
Quarry LP's Nurix Therapeutics position peaked at $56.2K in Q3 2024.
175 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2024.

Based on Quarry LP's 13F filing for Q4 2024, filed 14 Feb 2025.